Re: A new concept and treatment options for MS
Posted: Mon Jan 26, 2015 2:54 am
Hi Scott,
I am less convinced now that the fat metabolism lies at the origin. Instead, EBV infected cells secrete cytokines and chemokines as well as inhibitory cytokines. This may lead to subtle and less well understood immune defects, such as cytokine imbalance. I think here we arrive at the heart of cellular immunity. This Chapter Opening under the link explains. As you may see from the article, the immunological defects underlying EBV infection are not well understood.
http://informahealthcare.com/doi/abs/10 ... 014280.018
When the cells are in an emergency (in our case because of the virus attaching to e.g. its membranes), they may shed some AA in parallel to the cytokines. Biologically seen, this would make sense as it would help the cell because the internal balance of structural proteins would change towards anti-inflammatory ApoA1. Where I don’t exclude that the immune meta-system, besides being triggered by the parallel secretion of cytokines, has learned over the millions of years of evolution to recognize the AA leak as a sign that there is something wrong with the cell. The above thesis would need to be amended a bit accordingly.
Understanding the enormous complexity of our microcosm will be a daunting task. Notwithstanding, I think for all patients with MS the foremost important thing is to get the EBV virus down. Where there may be various possibilities for recovery, including stem cell therapy, liberation from ccsvi, strenthening CD8+ T-cell immunity etc, without getting the virus down the other therapies are unlikely to have a lasting effect.
To knock the virus down, there seem to be various options including vaccination, antiviral (e.g. Letermovir, Raltegravir), and chemo (e.g. Rituximab). Also what prof. Pender is doing with adoptive immunotherapy is very interesting in this regard.
The fascinating article under the link below sets out the EBV-infected autoreactive B-cell hypothesis which overlaps or complements with what we have seen here including on the development of meningeal B-cell follicles causing damage to the underlying cortex. What seems to be needed now is a team of experts who amalgamate the EBV-infected autoreactive B-cell hypothesis with our own thesis on MS.
http://www.nature.com/cti/journal/v3/n1 ... 1425a.html
After a long journey of 4 years, I feel fairly comfortable that here we have the right focus for finding the solution and a real cure for MS.
Leo
I am less convinced now that the fat metabolism lies at the origin. Instead, EBV infected cells secrete cytokines and chemokines as well as inhibitory cytokines. This may lead to subtle and less well understood immune defects, such as cytokine imbalance. I think here we arrive at the heart of cellular immunity. This Chapter Opening under the link explains. As you may see from the article, the immunological defects underlying EBV infection are not well understood.
http://informahealthcare.com/doi/abs/10 ... 014280.018
When the cells are in an emergency (in our case because of the virus attaching to e.g. its membranes), they may shed some AA in parallel to the cytokines. Biologically seen, this would make sense as it would help the cell because the internal balance of structural proteins would change towards anti-inflammatory ApoA1. Where I don’t exclude that the immune meta-system, besides being triggered by the parallel secretion of cytokines, has learned over the millions of years of evolution to recognize the AA leak as a sign that there is something wrong with the cell. The above thesis would need to be amended a bit accordingly.
Understanding the enormous complexity of our microcosm will be a daunting task. Notwithstanding, I think for all patients with MS the foremost important thing is to get the EBV virus down. Where there may be various possibilities for recovery, including stem cell therapy, liberation from ccsvi, strenthening CD8+ T-cell immunity etc, without getting the virus down the other therapies are unlikely to have a lasting effect.
To knock the virus down, there seem to be various options including vaccination, antiviral (e.g. Letermovir, Raltegravir), and chemo (e.g. Rituximab). Also what prof. Pender is doing with adoptive immunotherapy is very interesting in this regard.
The fascinating article under the link below sets out the EBV-infected autoreactive B-cell hypothesis which overlaps or complements with what we have seen here including on the development of meningeal B-cell follicles causing damage to the underlying cortex. What seems to be needed now is a team of experts who amalgamate the EBV-infected autoreactive B-cell hypothesis with our own thesis on MS.
http://www.nature.com/cti/journal/v3/n1 ... 1425a.html
After a long journey of 4 years, I feel fairly comfortable that here we have the right focus for finding the solution and a real cure for MS.
Leo